Natco Pharma Q3 Profit Soars 300% to Rs 212.7 Cr
By Rediff Money Desk, NEWDELHI Feb 14, 2024 14:51
Natco Pharma's net profit surged over 300% to Rs 212.7 crore in Q3 FY24 driven by strong revenue growth. Read more about the company's performance.
New Delhi, Feb 14 (PTI) Natco Pharma Ltd on Wednesday reported over three-fold rise in consolidated net profit at Rs 212.7 crore in the third quarter ended December 31, 2023 on the back of robust revenue growth.
The company had posted a consolidated net profit of Rs 62.3 crore in the same period last fiscal, Natco Pharma said in a regulatory filing.
Consolidated revenue from operations in the quarter under review stood at Rs 758.6 crore, as against Rs 492.5 crore in the year-ago period, it added.
Total expenses were higher at Rs 539.3 crore, up from Rs 431.9 crore in the same quarter last fiscal, the company said.
There was strong growth across businesses compared to last year, Natco said, adding it is confident of its strategy going forward.
Revenue from export of formulations was at Rs 605.6 crore in the third quarter, up from Rs 333.7 crore in the year-ago period.
However, domestic formulations revenue was down at Rs 99.4 crore, as compared to Rs 101.1 crore in the corresponding period last fiscal, it said.
Active pharmaceutical ingredients vertical clocked revenue of Rs 46.3 crore, up marginally from Rs 42.6 crore the same period a year ago, the company added.
Natco said its board of directors at their meeting held on February 14, 2024 have approved a third interim dividend of Rs 1.25 per equity share of Rs 2 each for the financial year 2023-24.
The company had posted a consolidated net profit of Rs 62.3 crore in the same period last fiscal, Natco Pharma said in a regulatory filing.
Consolidated revenue from operations in the quarter under review stood at Rs 758.6 crore, as against Rs 492.5 crore in the year-ago period, it added.
Total expenses were higher at Rs 539.3 crore, up from Rs 431.9 crore in the same quarter last fiscal, the company said.
There was strong growth across businesses compared to last year, Natco said, adding it is confident of its strategy going forward.
Revenue from export of formulations was at Rs 605.6 crore in the third quarter, up from Rs 333.7 crore in the year-ago period.
However, domestic formulations revenue was down at Rs 99.4 crore, as compared to Rs 101.1 crore in the corresponding period last fiscal, it said.
Active pharmaceutical ingredients vertical clocked revenue of Rs 46.3 crore, up marginally from Rs 42.6 crore the same period a year ago, the company added.
Natco said its board of directors at their meeting held on February 14, 2024 have approved a third interim dividend of Rs 1.25 per equity share of Rs 2 each for the financial year 2023-24.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.93 ( -4.87)
- 226206286
- IFL Enterprises
- 1.30 (+ 4.84)
- 81461564
- Vodafone Idea L
- 16.79 (+ 0.66)
- 67447398
- NCL Research
- 0.95 ( -4.04)
- 31996628
- Franklin Industries
- 3.73 (+ 3.32)
- 21511209
MORE NEWS
![Navi Mumbai...](https://im.rediff.com/80-80/money/2021/jun/10navi-mumbai-airport7.jpg)
Navi Mumbai Airport ILS Signal Testing Begins
The Airports Authority of India (AAI) has begun ILS signal testing at the...
![Air India VRS for...](https://im.rediff.com/80-80/money/2020/sep/09tata-vistara-3.jpg)
Air India VRS for Non-Flying Staff Ahead of...
Air India has announced a voluntary retirement scheme (VRS) and voluntary separation...
Fisher Groups Oppose WTO Fisheries Subsidy Talks
Small-scale fisher groups from India, Indonesia, and Bangladesh demand WTO keep...